Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey Buys 30,000 Shares

Aprea Therapeutics, Inc. (NASDAQ:APRE) Director Marc Duey purchased 30,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average cost of $4.39 per share, with a total value of $131,700.00. Following the acquisition, the director now directly owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Marc Duey also recently made the following trade(s):

• On Monday, October 14th, Marc Duey purchased 190 shares of Aprea Therapeutics stock. The shares were bought at an average cost of $2.58 per share, with a total value of $490.20.

Aprea Therapeutics Stock Up 27.1 %

Shares of Aprea Therapeutics stock opened at $4.45 on Friday. The stock’s 50-day simple moving average is $3.18 and its 200-day simple moving average is $4.19. Aprea Therapeutics, Inc. has a 52 week low of $2.15 and a 52 week high of $8.85. The company has a market capitalization of $24.16 million, a price-to-earnings ratio of -1.34 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last posted its earnings results on Monday, August 12th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.05. The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. On average, equities analysts expect that Aprea Therapeutics, Inc. will post -2.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on APRE. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research report on Monday, August 12th. Wedbush restated an “outperform” rating and issued a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics makes up 0.5% of Stonepine Capital Management LLC’s holdings, making the stock its 21st largest position. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.